(2S)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid
• 化学式: C₇H₁₃NO₃S₂
• 分子量: 223.3
• InChiKey: VUAFHZCUKUDDBC-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  68.4
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate 生成 (2S)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid
  参考文献：
  名称：

  MORITA, TAKAKADZU;ISO, TADASI;KAVASIMA, JOITI

  摘要：

  DOI：

文献信息

• Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith
  申请人：Philippe Michel

  公开号：US20060013784A1

  公开（公告）日：2006-01-19

  The present disclosure relates to specific dimercaptoamides, reducing compositions for permanently reshaping keratin fibers comprising the dimercaptoamides, for instance, human keratin fibers such as the hair; and processes for reshaping keratin fibers comprising the application of said reducing compositions. The present disclosure also relates to processes for preparing the dimercaptoamides.

  本公开涉及特定的二硫代酰胺，用于永久性重塑角蛋白纤维的还原组合物，例如人类角蛋白纤维，如头发；以及包括应用所述还原组合物在内的重塑角蛋白纤维的过程。本公开还涉及制备二硫代酰胺的过程。
• Utilisation de dimercaptoamides pour la déformation permanente des fibres kératiniques
  申请人：L'OREAL

  公开号：EP1584615A1

  公开（公告）日：2005-10-12

  L'invention concerne l'utilisation, en tant qu'agents réducteurs pour la déformation permanente des fibres kératiniques, et notamment des fibres kératiniques humains telles que les cheveux, de dimercaptoamides particuliers.

  本发明涉及使用特定的二巯基氨基甲酸酯作为还原剂，使角蛋白纤维，特别是人类角蛋白纤维（如头发）永久变形。
• MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS
  申请人：Altibio, Inc.

  公开号：EP3658130A1

  公开（公告）日：2020-06-03
• US7875268B2
  申请人：——

  公开号：US7875268B2

  公开（公告）日：2011-01-25
• [EN] MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS<br/>[FR] COMPOSITIONS DE BUCILLAMINE À LIBÉRATION MODIFIÉE, KITS ET MÉTHODES POUR TRAITER LA CYSTINURIE, L'ARTHRITE, LA GOUTTE ET AUTRES TROUBLES APPARENTÉS
  申请人：ALTIBIO INC

  公开号：WO2019023346A1

  公开（公告）日：2019-01-31

  The present invention provides methods, compositions, devices, and kits for treating cystinuria and related disorders, in which bucillamine is administered to a patient according to a modified- release strategy that releases bucillamine, preferably in the stomach, in critically-spaced, repeated pulses over time, to provide lower peak plasma levels of total bucillamine, but consistently higher free drug levels in urine, for binding cystine. In particular, use of the present modified-release formulations and systems reduce side effects of bucillamine and achieve efficacy with less frequent administrations and/or lower dosage than immediate-release forms. The present strategies also find use in treating inflammatory conditions, like rheumatoid arthritis, gout, where bucillamine is administered in a different modified-release strategy that releases bucillamine in more closely critically-spaced pulses, again preferably in the stomach, to provide lower peak blood levels of total bucillamine, but higher and steadier blood levels of unbound drug, which improve availability in treating such conditions.